Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Tina Nova, Mark Guyer


Illumina has hired Tina Nova to be senior vice president and general manager of the firm's oncology business. Rick Klausner has been serving as interim oncology leader since January and will continue in his role as senior vice president and chief medical officer.

Nova is cofounder of molecular diagnostic company Genoptix and served as its president and CEO from 2000. She also cofounded Nanogen, a provider of MDx tests, and served as its COO and president from 1994 until 2000. She holds a BS in biological sciences from the University of California, Irvine and a PhD in biochemistry from the University of California, Riverside.

Mark Guyer has retired from his post as deputy director of the National Human Genome Research Institute.

Guyer has worn many hats at NHGRI since he joined the Office of Human Genome Research, the institute's precursor, in 1998, and he helped guide NHGRI's research activities from the earliest days of the Human Genome Project. He contributed to "making the various parts of the HGP come together as a working project," NHGRI said, and helped NHGRI come together as an organization. Although he was not the architect of the HGP, he played an "indispensable" role in so many aspects of the project, NIH Director Francis Collins said.

In 2002, Guyer became director of the NHGRI Division of Extramural Research, now the Extramural Research Program, and he has had a hand in establishing programs such as the 1,000 Genomes Project; the Large-Scale Genome Sequencing and Analysis Centers; the Ethical, Legal and Social Implications research program; and The Cancer Genome Atlas project, among others.

Although he officially retired on June 30, Guyer will continue to work at NHGRI on a part-time basis on the H3Africa Program and the Big Data to Knowledge initiative.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.